Skip to main content
Premium Trial:

Request an Annual Quote

People in the News at Myriad Genetics, Oxford Nanopore, Quest Diagnostics, Cardio Diagnostics, More

Myriad Genetics: Bryan Riggsbee, Scott Leffler

Myriad Genetics has appointed Scott Leffler as CFO, effective Jan. 29, 2024. Leffler will succeed current CFO Bryan Riggsbee, who is retiring and will stay on as a strategic advisor through March 31. Leffler previously served as CFO of Clover Health and as CFO and Treasurer of Sotera Health.

Oxford Nanopore Technologies: Sarah Fortune, Heather Preston, Sarah Gordon Wild, Wendy Becker

Oxford Nanopore Technologies has appointed Sarah Fortune and Heather Preston as non-executive directors. Fortune is a professor of immunology and infectious diseases at the Harvard T.H. Chan School of Public Health. She holds an MD from Columbia University and a BS in biology from Yale University. Preston most recently served as a managing partner of San Francisco-based Pivotal BioVentures. She holds a medical degree from the University of Oxford and a BS in biochemistry from St Bartholomew's Hospital Medical School at the University of London. Additionally, Oxford Nanopore announced the retirement of non-executive directors Sarah Gordon Wild and Wendy Becker from its board.

Quest Diagnostics: Yuri Fesko

Quest Diagnostics has named Yuri Fesko senior VP and chief medical officer. He replaces Jay Wohlgemuth, who held the role until he stepped down in early 2023. Fesko has served in a number of roles at Quest since joining the company in 2016, most recently as VP of medical affairs and senior medical director for oncology services. Among other achievements, he led the clinical development of the company's 500-gene somatic tumor NGS panel, as well as clinical research on minimal residual disease test technology developed by Haystack Oncology, which Quest acquired earlier this year. Prior to joining Quest, he was medical director of oncology for the Duke Cancer Center and chief of oncology for Wake County in North Carolina. Fesko holds MD and bachelor's degrees from Case Western Reserve University.

Cardio Diagnostics: Paul Burton

Paul Burton has been appointed to the board of directors of Cardio Diagnostics as an independent director. He will chair the nominating and corporate governance committee and be a member of the audit committee. Burton is a managing partner at 2Flo Ventures and CEO of Akan Biosciences. Previously, he was CEO of several venture-based therapeutics companies. He holds JD and MBA degrees from the University of Illinois Urbana-Champaign.

Metrion Biosciences: David Milroy, Steve Carle

Metrion Biosciences has made a series of changes to its board of directors. David Milroy has joined the firm's board as the investor director for Maven Capital Partners and Steve Carle has replaced Maya Ward as the board representative for Gresham House Ventures. Marc Rogers, Barry Kenny and Mark Keogh have retired as non-executive directors.

For additional recent items on executive appointments, promotions, and departures in the omics and molecular diagnostics space, please see the People in the News page on our website.